Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00366431 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

A Phase 2 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 2
Development phase
420
Enrollment target

NCT00366431: Completed Phase 2 study, sponsored by Bausch Health Americas.

NCT00366431 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 420 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00366431, a Phase 2 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 2
Development phase
420 participants
Enrollment target

Study Summary

The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.

Interventions

  • DRUG MOA-728

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2006-08
Est. Completion 2007-03
Phase Phase 2
Bausch Health Americas

168 total trials

What the finished NCT00366431 record still lists

NCT00366431 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher).

The record links to 0 conditions, and to 1 intervention - of which MOA-728 is the first listed.

NCT00366431 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00366431 about?

NCT00366431 is a clinical study titled "Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain". The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.

What is the current status of trial NCT00366431?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2006-08. Estimated completion is 2007-03.

What interventions are being tested in trial NCT00366431?

The interventions under investigation include: MOA-728 (DRUG).

Who is sponsoring clinical trial NCT00366431?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00366431's enrollment target sits among peer trials

420 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01790152 · 420 participants

    Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • NCT02701244 · 420 participants

    A Registry Study of Breast Microseed Treatment

  • NCT02966665 · 420 participants · Phase 1

    : Vascular Function in Health and Disease

  • NCT04149743 · 420 participants · NA

    HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00366431, the US trial registry maintained by the National Library of Medicine. NCT00366431 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.